Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology

Parkinson, 1817

Sung, 2013, Nonmotor symptoms in Parkinson's disease: expanding the view of Parkinson's disease beyond a pure motor, pure dopaminergic problem, Neurol Clin, 31, S1, 10.1016/j.ncl.2013.04.013

Poewe, 2017, Parkinson disease, Nat Rev Dis Primers, 3, 17013, 10.1038/nrdp.2017.13

Fearnley, 1991, Ageing and Parkinson's disease: substantia nigra regional selectivity, Brain, 114, 2283, 10.1093/brain/114.5.2283

Marras, 2018, Prevalence of Parkinson's disease across North America, NPJ Parkinsons Dis, 4, 21, 10.1038/s41531-018-0058-0

Twelves, 2003, Systematic review of incidence studies of Parkinson's disease, Mov Disord, 18, 19, 10.1002/mds.10305

Pinter, 2015, Mortality in Parkinson's disease: a 38-year follow-up study, Mov Disord, 30, 266, 10.1002/mds.26060

Dorsey, 2018, The emerging evidence of the Parkinson pandemic, J Parkinsons Dis, 8, S3

Kaltenboeck, 2012, Direct costs and survival of medicare beneficiaries with early and advanced Parkinson's disease, Parkinsonism Relat Disord, 18, 321, 10.1016/j.parkreldis.2011.11.015

Goldman, 2019, Concordance for Parkinson's disease in twins: a 20-year update, Ann Neurol, 85, 600, 10.1002/ana.25441

Tanner, 2014, The disease intersection of susceptibility and exposure: chemical exposures and neurodegenerative disease risk, Alzheimers Dement, 10, S213, 10.1016/j.jalz.2014.04.014

Goldman, 2014, Environmental toxins and Parkinson's disease, Annu Rev Pharmacol Toxicol, 54, 141, 10.1146/annurev-pharmtox-011613-135937

Furlong, 2015, Protective glove use and hygiene habits modify the associations of specific pesticides with Parkinson's disease, Environ Int, 75, 144, 10.1016/j.envint.2014.11.002

Kamel, 2014, Dietary fat intake, pesticide use, and Parkinson's disease, Parkinsonism Relat Disord, 20, 82, 10.1016/j.parkreldis.2013.09.023

Weisskopf, 2012, Polychlorinated biphenyls in prospectively collected serum and Parkinson's disease risk, Mov Disord, 27, 1659, 10.1002/mds.25217

Goldman, 2012, Solvent exposures and Parkinson disease risk in twins, Ann Neurol, 71, 776, 10.1002/ana.22629

Criswell, 2018, [(18)F]FDOPA positron emission tomography in manganese-exposed workers, Neurotoxicology, 64, 43, 10.1016/j.neuro.2017.07.004

Racette, 2017, Dose-dependent progression of parkinsonism in manganese-exposed welders, Neurology, 88, 344, 10.1212/WNL.0000000000003533

Harischandra, 2019, Manganese promotes the aggregation and prion-like cell-to-cell exosomal transmission of alpha-synuclein, Sci Signal, 12, 10.1126/scisignal.aau4543

Kenborg, 2012, Parkinson's disease and other neurodegenerative disorders among welders: a Danish cohort study, Mov Disord, 27, 1283, 10.1002/mds.25125

Finkelstein, 2007, A study of the relationships between Parkinson's disease and markers of traffic-derived and environmental manganese air pollution in two Canadian cities, Environ Res, 104, 420, 10.1016/j.envres.2007.03.002

Kenborg, 2015, Head injury and risk for Parkinson disease: results from a Danish case-control study, Neurology, 84, 1098, 10.1212/WNL.0000000000001362

Morens, 1996, Epidemiologic observations on Parkinson's disease: incidence and mortality in a prospective study of middle-aged men, Neurology, 46, 1044, 10.1212/WNL.46.4.1044

Ritz, 2007, Pooled analysis of tobacco use and risk of Parkinson disease, Arch Neurol, 64, 990, 10.1001/archneur.64.7.990

Ross, 2000, Association of coffee and caffeine intake with the risk of Parkinson disease, JAMA, 283, 2674, 10.1001/jama.283.20.2674

Ascherio, 2016, The epidemiology of Parkinson's disease: risk factors and prevention, Lancet Neurol, 15, 1257, 10.1016/S1474-4422(16)30230-7

Park, 2005, Consumption of milk and calcium in midlife and the future risk of Parkinson disease, Neurology, 64, 1047, 10.1212/01.WNL.0000154532.98495.BF

Gao, 2007, Prospective study of dietary pattern and risk of Parkinson disease, Am J Clin Nutr, 86, 1486, 10.1093/ajcn/86.5.1486

Yang, 2015, Physical activity and risk of Parkinson's disease in the Swedish National March cohort, Brain, 138, 269, 10.1093/brain/awu323

Kim, 2018, Integration of risk factors for Parkinson disease in 2 large longitudinal cohorts, Neurology, 90, e1646, 10.1212/WNL.0000000000005473

Polymeropoulos, 1997, Mutation in the alpha-synuclein gene identified in families with Parkinson's disease, Science, 276, 2045, 10.1126/science.276.5321.2045

Singleton, 2003, alpha-Synuclein locus triplication causes Parkinson's disease, Science, 302, 841, 10.1126/science.1090278

Kitada, 1998, Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism, Nature, 392, 605, 10.1038/33416

Valente, 2004, Hereditary early-onset Parkinson's disease caused by mutations in PINK1, Science, 304, 1158, 10.1126/science.1096284

Shin, 2011, PARIS (ZNF746) repression of PGC-1alpha contributes to neurodegeneration in Parkinson's disease, Cell, 144, 689, 10.1016/j.cell.2011.02.010

Zheng, 2010, PGC-1alpha, a potential therapeutic target for early intervention in Parkinson's disease, Sci Transl Med, 2, 52ra73, 10.1126/scitranslmed.3001059

Greenamyre, 2003, The rotenone model of Parkinson's disease: genes, environment and mitochondria, Parkinsonism Relat Disord, 9, S59, 10.1016/S1353-8020(03)00023-3

Tanner, 2011, Rotenone, paraquat, and Parkinson's disease, Environ Health Perspect, 119, 866, 10.1289/ehp.1002839

Bonifati, 2003, Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism, Science, 299, 256, 10.1126/science.1077209

Raninga, 2017, The multifaceted roles of DJ-1 as an antioxidant, Adv Exp Med Biol, 1037, 67, 10.1007/978-981-10-6583-5_6

Alessi, 2018, LRRK2 kinase in Parkinson's disease, Science, 360, 36, 10.1126/science.aar5683

West, 2007, Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity, Hum Mol Genet, 16, 223, 10.1093/hmg/ddl471

Hatcher, 2017, Small-molecule inhibitors of LRRK2, Adv Neurobiol, 14, 241, 10.1007/978-3-319-49969-7_13

Giaime, 2017, Age-dependent dopaminergic neurodegeneration and impairment of the autophagy-lysosomal pathway in LRRK-deficient mice, Neuron, 96, 796, 10.1016/j.neuron.2017.09.036

Clark, 2005, Pilot association study of the beta-glucocerebrosidase N370S allele and Parkinson's disease in subjects of Jewish ethnicity, Mov Disord, 20, 100, 10.1002/mds.20320

Riboldi, 2019, GBA, Gaucher disease, and Parkinson's disease: from genetic to clinic to new therapeutic approaches, Cells, 8, 10.3390/cells8040364

Balestrino, 2018, Glucocerebrosidase and Parkinson disease: molecular, clinical, and therapeutic implications, Neuroscientist, 24, 540, 10.1177/1073858417748875

Kannarkat, 2013, The role of innate and adaptive immunity in Parkinson's disease, J Parkinsons Dis, 3, 493

Rolli-Derkinderen, 2019, Is Parkinson's disease a chronic low-grade inflammatory bowel disease?, J Neurol

De Pablo-Fernandez, 2018, Association between diabetes and subsequent Parkinson disease: a record-linkage cohort study, Neurology, 91, e139, 10.1212/WNL.0000000000005771

Hamza, 2010, Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease, Nat Genet, 42, 781, 10.1038/ng.642

Nalls, 2019, Parkinson’s disease genetics: identifying novel risk loci, providing causal insights and improving estimates of heritable risk, bioRxiv, 388165

Lin, 2012, Somatic mitochondrial DNA mutations in early Parkinson and incidental Lewy body disease, Ann Neurol, 71, 850, 10.1002/ana.23568

van Heesbeen, 2019, Entanglement of genetics and epigenetics in Parkinson's disease, Front Neurosci, 13, 277, 10.3389/fnins.2019.00277

Kalia, 2015, Disease-modifying strategies for Parkinson's disease, Mov Disord, 30, 1442, 10.1002/mds.26354

Savitt, 2019, Targeting alpha-synuclein in Parkinson's disease: progress towards the development of disease-modifying therapeutics, Drugs, 79, 797, 10.1007/s40265-019-01104-1

Wyse, 2016, Nilotinib - differentiating the hope from the hype, J Parkinsons Dis, 6, 519

Schneider, 2017, Neuropathology of genetic synucleinopathies with parkinsonism: review of the literature, Mov Disord, 32, 1504, 10.1002/mds.27193

Burre, 2018, Cell biology and pathophysiology of alpha-synuclein, Cold Spring Harb Perspect Med, 8, 10.1101/cshperspect.a024091

Braak, 2003, Staging of brain pathology related to sporadic Parkinson's disease, Neurobiol Aging, 24, 197, 10.1016/S0197-4580(02)00065-9

Braak, 2017, Neuropathological staging of brain pathology in sporadic Parkinson's disease: separating the wheat from the chaff, J Parkinsons Dis, 7, S71

Beach, 2009, Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction, Acta Neuropathol, 117, 613, 10.1007/s00401-009-0538-8

Postuma, 2016, Advances in markers of prodromal Parkinson disease, Nat Rev Neurol, 12, 622, 10.1038/nrneurol.2016.152

Lionnet, 2018, Does Parkinson's disease start in the gut?, Acta Neuropathol, 135, 1, 10.1007/s00401-017-1777-8

van de Berg, 2012, Patterns of alpha-synuclein pathology in incidental cases and clinical subtypes of Parkinson's disease, Parkinsonism Relat Disord, 18, S28, 10.1016/S1353-8020(11)70011-6

Brundin, 2017, Prying into the prion hypothesis for Parkinson's disease, J Neurosci, 37, 9808, 10.1523/JNEUROSCI.1788-16.2017

Johnson, 2019, Triggers, facilitators, and aggravators: redefining Parkinson's disease pathogenesis, Trends Neurosci, 42, 4, 10.1016/j.tins.2018.09.007

Espay, 2019, Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases, Neurology, 92, 329, 10.1212/WNL.0000000000006926

Ross, 2012, Pre-motor features of Parkinson's disease: the Honolulu-Asia aging study experience, Parkinsonism Relat Disord, 18, S199, 10.1016/S1353-8020(11)70062-1